Skip to Content

A new study shows that PTCD and MRD are complementary and necessary for doing a whole assessment on patient-response for myeloma patients

In this MEDtalk, Jakob Nordberg Nørgaard, associated research doctor, Ph.D. student; MD from Oslo, shares some of his findings from his latest phase II study; carfilzomib-lenalidomide-dexamethasone consolidation in myeloma patients with a positive FDG PET/CT after upfront autologous stem cell transplantation.

Jakob Nordberg Nørgaard

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top